Tag
A large Swedish cohort study reveals that dental diseases and tooth loss are associated with increased risk of primary liver cancer, highlighting the importance of oral health in systemic disease prevention.
This study demonstrates that nucleos(t)ide analogue therapy significantly reduces cirrhosis and hepatocellular carcinoma risk in specific HBeAg-positive chronic HBV infection phases beyond current EASL 2025 treatment indications.
Complete pathologic response (cPR) after locoregional therapies notably improves survival in hepatocellular carcinoma (HCC) patients undergoing liver transplantation. Yttrium-90 radioembolization shows superior cPR rates, particularly when
TESERA leverages computational pathology to classify hepatocellular carcinoma into biologically distinct morphologic subtypes from standard H&E slides, offering accurate prognosis stratification competitive with clinical and molecular m
This review synthesizes recent evidence on immune checkpoint inhibitor (ICI)-based downstaging therapy for hepatocellular carcinoma (HCC) beyond Milan criteria prior to liver transplantation, highlighting improved oncologic outcomes alongsi
A multidisciplinary consensus provides practical, trial-design focused recommendations for testing systemic therapies around surgery or combined with locoregional treatment in hepatocellular carcinoma, emphasizing patient selection, endpoin
This review assesses the clinical utility of steatotic liver disease risk scores in predicting cirrhosis and hepatocellular carcinoma, highlighting the superior performance of the SAFE score for cirrhosis and challenges in HCC risk predicti
The RADICAL consortium’s large-scale study reveals a high long-term transition rate from immune tolerant to immune active chronic hepatitis B, especially in patients with high-normal ALT, suggesting the need for closer monitoring and
This study reveals how the S1P-TREM2-NRF2 signaling pathway protects tumor-associated neutrophils from ferroptosis, sustaining immunosuppression and promoting hepatocellular carcinoma progression, offering new therapeutic avenues.
This study elucidates how distinct patterns and gradations of vascular invasion in hepatocellular carcinoma differentially impact recurrence timing and overall survival, enabling improved postoperative risk stratification.
This article explores how genetic variants affect CPEB3-mediated alternative polyadenylation in hepatocellular carcinoma, revealing potential prognostic markers and therapeutic targets to improve patient survival.
Distinct gut microbial profiles but shared metabolomic markers, especially fecal acetate, predict response and survival with combination immunotherapy in metabolic dysfunction-associated and viral hepatitis-related hepatocellular carcinoma.
NEK7 promotes acquired lenvatinib resistance in hepatocellular carcinoma by phosphorylating EGFR at serine 1070, activating key signaling pathways. Blocking this interaction offers a promising therapeutic avenue to counteract resistance.
This article explores the unique genomic and transcriptomic features of hepatocellular carcinoma in Fontan-associated liver disease, revealing distinct mutation patterns and poor-prognosis molecular subtypes that inform disease mechanisms a
BEACON-HCC is a multidisciplinary, evidence-based North American consensus that updates HCC treatment allocation—integrating tumor biology, nuanced intrahepatic burden, vascular invasion, and newer modalities (EBRT, TARE, systemic–locoregio
Circulating extracellular vesicles carrying PD-1, PD-L1, and CTLA-4 can non-invasively predict responses and early resistance to immune checkpoint inhibitors in advanced hepatocellular carcinoma, improving patient stratification and managem
RIPPLY1 suppresses cancer stemness by targeting TBX19, improving prognosis in CTNNB1-mutated hepatocellular carcinoma through inhibition of tumor progression.
The phase 3 TORCH trial demonstrates that adding selective radiofrequency ablation after transarterial chemoembolization significantly improves progression-free and overall survival in patients with unresectable liver-confined hepatocellula
This study evaluates the long-term incidence of liver cancer in chronic hepatitis B patients who clear hepatitis B surface antigen, finding significantly reduced cancer risk in younger patients without cirrhosis.
Combining circulating methylated SEPT9 with alpha-fetoprotein significantly enhances early hepatocellular carcinoma detection in cirrhotic patients, outperforming AFP alone and allowing improved surveillance sensitivity and specificity.
